Z-VAD-FMK C22H30FN307

Z-VAD-FMK C22H30FN307

Contact us: [email protected]

Z-VAD-FMK
A1902-5 5 mg
EUR 268.8
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK
A1902-5.1 10 mM (in 1mL DMSO)
EUR 268.8
Description: Z-VAD-FMK, an inhibitor of ICE-like proteases, inhibits apoptosis in THP.1 cells induced by diverse stimuli1 and Fas antigen-induced apoptosis in Jurkat T-cells2.

Z-VAD-FMK
abx076838-1mg 1 mg
EUR 410.4

Z-VAD-FMK
HY-16658B 10mg
EUR 786

Z-VAD-FMK
13300-1mg 1 mg
EUR 102
Description: Z-VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone) is a cell-permeable, irreversible pan caspase inhibitor that binds to the catalytic site of caspase proteases and can inhibit induction of apoptosis.

mFluorâ„¢ 510-VAD-FMK
13476-25Tests 25 Tests
EUR 109
Description: FAM-VAD is a green fluorescent cell-permeable polycaspase inhibitor to target caspases 1, 2, 3, 6, 8, 9, or 10.

Z-VAD-FMK, Methyl Ester
27017 1 mg
EUR 165
Description: Z-VAD(OMe)-FMK is a cell permeable, irreversible pan-caspase inhibitor and anti-apoptotic agent. It has been shown to inhibit Fas-mediated apoptosis in Jurkat T cells and apoptosis in THP.1 cells induced by diverse stimuli (including cycloheximide, thapsigargin, etoposide and staurosporine). Inhibits caspases 1, 3, 4, and 7._x000D__x000D_ _x000D_

Z-VAD-FMK, cell permeable
GL1523-1MG 1 mg
EUR 330

Z-VAD-FMK, cell permeable
GL1523-5MG 5 mg
EUR 950.4

mFluor™ 510-VAD-FMK
13476 25 Tests
EUR 109

mFluorâ„¢ Violet 450-VAD-FMK
13475-25Tests 25 Tests
EUR 109
Description: FAM-VAD is a blue fluorescent cell-permeable polycaspase inhibitor to target caspases 1, 2, 3, 6, 8, 9, or 10.

Caspase-Family Inhibitor Z-VAD-FMK
1010-100 each
EUR 235.2

Caspase-Family Inhibitor Z-VAD-FMK
1010-20C each
EUR 235.2

mFluor™ Violet 450-VAD-FMK
13475 25 Tests
EUR 109

SRB-VAD-FMK [Sulforhodamine B-VAD-FMK]
13472 25 Tests
EUR 109

SRB-VAD-FMK [Sulforhodamine B-VAD-FMK]
13482 100 Tests
EUR 211

SRB-VAD-FMK [Sulforhodamine B-VAD-FMK]
13472-25Tests 25 Tests
EUR 109
Description: SRB-VAD is a red fluorescent cell-permeable polycaspase inhibitor to target caspases 1, 2, 3, 6, 8, 9, or 10.

SRB-VAD-FMK [Sulforhodamine B-VAD-FMK]
13482-100Tests 100 Tests
EUR 211
Description: SRB-VAD is a red fluorescent cell-permeable polycaspase inhibitor to target caspases 1, 2, 3, 6, 8, 9, or 10.

Z-VAD-FMK (Pan-specific caspase inhibitor)
SIH-557-1MG 1 mg
EUR 231.6
Description: The substance Z-VAD-FMK is a pan-specific caspase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is lyophilized solid or wax which is May be dissolved in DMSO (10 mg/ml).

Biotin-VAD-FMK
1123-20C each
EUR 392.4

FAM-VAD-FMK
13470 25 Tests
EUR 109

TF4-VAD-FMK
13471 25 Tests
EUR 109

FAM-VAD-FMK
13484 100 Tests
EUR 211

FITC-VAD-FMK
9497-100 each
EUR 430.8

Biotin-VAD-FMK
HY-100894 1mg
EUR 1216.8

FAM-VAD-FMK
13470-25Tests 25 Tests
EUR 109
Description: FAM-VAD is a green fluorescent cell-permeable polycaspase inhibitor to target caspases 1, 2, 3, 6, 8, 9, or 10.

TF4-VAD-FMK
13471-25Tests 25 Tests
EUR 109
Description: TF4-VAD is a red fluorescent cell-permeable polycaspase inhibitor to target caspases 1, 2, 3, 6, 8, 9, or 10.

FAM-VAD-FMK
13484-100Tests 100 Tests
EUR 211
Description: FAM-VAD is a green fluorescent cell-permeable polycaspase inhibitor to target caspases 1, 2, 3, 6, 8, 9, or 10.

Z-YVAD-FMK
1141-1 each
EUR 405.6

Z-YVAD-FMK
1141-5 each
EUR 966

Z-VDVAD-FMK
1142-1 each
EUR 366

Z-VDVAD-FMK
1142-5 each
EUR 966

Z-DEVD-FMK
1143-1 each
EUR 379.2

Z-DEVD-FMK
1143-5 each
EUR 966

Z-IETD-FMK
1148-1 each
EUR 392.4

Z-IETD-FMK
1148-5 each
EUR 940.8

Z-LEHD-FMK
1149-1 each
EUR 379.2

Z-LEHD-FMK
1149-5 each
EUR 920.4

Z-ATAD-FMK
1152-1 each
EUR 418.8

Z-ATAD-FMK
1152-5 each
EUR 1096.8

Z-LEVD-FMK
1144-1 each
EUR 379.2

Z-LEVD-FMK
1144-5 each
EUR 966

Z-VEID-FMK
1146-1 each
EUR 366

Z-VEID-FMK
1146-5 each
EUR 966

Z-FA-FMK
1986-1 each
EUR 176.4

Z-FA-FMK
1986-5 each
EUR 444

Z-DEVD-FMK
13303 1 mg
EUR 102

Z-IETD-FMK
13305 1 mg
EUR 102

Z-LETD-FMK
13307 1 mg
EUR 102

Z-DEVD-FMK
27314 5 mg
EUR 215
Description: Caspase-3 Inhibitor

Z-DQMD-FMK
27666-1 5 mg
EUR 215
Description: Z-DQMD-FMK is a synthetic peptide that irreversibly inhibits the activity of Caspase-3. Inhibits MG 132-induced small cell lung cancer cell death in vitro. Z-DQMD-FMK can be used for both in vitro and in vivo studies--see note for using this product in vitro.

Z-DQMD-FMK
27666-2 10 mg
EUR 325
Description: Z-DQMD-FMK is a synthetic peptide that irreversibly inhibits the activity of Caspase-3. Inhibits MG 132-induced small cell lung cancer cell death in vitro. Z-DQMD-FMK can be used for both in vitro and in vivo studies--see note for using this product in vitro.

Z-DQMD-FMK
27666-3 25 mg
EUR 500
Description: Z-DQMD-FMK is a synthetic peptide that irreversibly inhibits the activity of Caspase-3. Inhibits MG 132-induced small cell lung cancer cell death in vitro. Z-DQMD-FMK can be used for both in vitro and in vivo studies--see note for using this product in vitro.

Z-FA-FMK
27667-1 5 mg
EUR 290

Z-FA-FMK
27667-2 25 mg
EUR 500

Z-FA-FMK
27667-3 10 mg
EUR 440

Z-VDVAD-FMK
27668-1 5 mg
EUR 380
Description: Z-VDVAD-FMK is a synthetic peptide that irreversibly inhibits the activity of caspase-2. It attenuates oxyhemoglobin-induced cleavage of PARP and apoptosis in endothelial cells. Z-VDVAD-FMK can be used for both in vitro and in vivo studies--see note for using this product in vitro.

Z-VDVAD-FMK
27668-2 10 mg
EUR 625
Description: Z-VDVAD-FMK is a synthetic peptide that irreversibly inhibits the activity of caspase-2. It attenuates oxyhemoglobin-induced cleavage of PARP and apoptosis in endothelial cells. Z-VDVAD-FMK can be used for both in vitro and in vivo studies--see note for using this product in vitro.

Z-VEID-FMK
27669-1 5 mg
EUR 380
Description: Z-VEID-FMK is a synthetic peptide that irreversibly inhibits activity of VEID-dependent caspases (e.g., caspase-6). The inhibitor is designed as a methyl ester to facilitate cell permeability. Can be used for both in vitro and in vivo studies--see note for using this product in vitro.

Z-VEID-FMK
27669-2 10 mg
EUR 625
Description: Z-VEID-FMK is a synthetic peptide that irreversibly inhibits activity of VEID-dependent caspases (e.g., caspase-6). The inhibitor is designed as a methyl ester to facilitate cell permeability. Can be used for both in vitro and in vivo studies--see note for using this product in vitro.

Z-DEVD-FMK
A1920-1 1 mg
EUR 135.6
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-10 10 mg
EUR 408
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-25 25 mg
EUR 616.8
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-5 5 mg
EUR 268.8
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-5.1 10 mM (in 1mL DMSO)
EUR 351.6
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DEVD-FMK
A1920-S Evaluation Sample
EUR 97.2
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death.

Z-DQMD-FMK
A1921-1 1 mg
EUR 135.6
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-10 10 mg
EUR 408
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-25 25 mg
EUR 616.8
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-5 5 mg
EUR 268.8
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-5.1 10 mM (in 1mL DMSO)
EUR 518.4
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-DQMD-FMK
A1921-S Evaluation Sample
EUR 97.2
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1.

Z-VDVAD-FMK
A1922-1 1 mg
EUR 212.4
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-10 10 mg
EUR 756
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-25 25 mg
EUR 1173.6
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-5 5 mg
EUR 477.6
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VDVAD-FMK
A1922-S Evaluation Sample
EUR 97.2
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1.

Z-VEID-FMK
A1923-1 1 mg
EUR 212.4
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-10 10 mg
EUR 756
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-25 25 mg
EUR 1173.6
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-5 5 mg
EUR 477.6
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-VEID-FMK
A1923-S Evaluation Sample
EUR 97.2
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK).

Z-WEHD-FMK
A1924-1 1 mg
EUR 135.6
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK
A1924-10 10 mg
EUR 408
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-WEHD-FMK
A1924-25 25 mg
EUR 616.8
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84.

Z-VAD-FMK C22H30FN307